AIM ImmunoTech

AIMPhase 3

AIM ImmunoTech is dedicated to advancing immunology solutions with its lead immuno-modulator, Ampligen. The company has a diversified pipeline targeting oncology, viral diseases like COVID-19, and immune disorders such as ME/CFS, with clinical programs underway at major research centers. Its strategic focus is on developing Ampligen as a combinational therapy for solid tumors and addressing post-viral syndromes, positioning it in several large and growing therapeutic markets.

Focus

BiologicsSmall Molecules

AIM · Stock Price

USD 128031.04+0.00 (+0.00%)

Historical price data

AI Company Overview

Technology Platform

Ampligen® (rintatolimod) is a double-stranded RNA (dsRNA) immuno-modulator and Toll-like receptor 3 (TLR3) agonist designed to stimulate the body's innate immune response against tumors and viral infections.

Pipeline Snapshot

14 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Ampligen	Chronic Fatigue Syndrome	Phase 3
EC Aspirin + Recombinant Interferon Alfa-2b + Rintatolimod	Prostate Adenocarcinoma	Phase 2
Rintatolimod	Pancreatic Cancer	Phase 2
poly I-poly C12U	HIV Seropositivity	Phase 2
poly I-poly C12U	HIV Seropositivity	Phase 2

Funding History

Total raised: $24M

PIPE$15MUndisclosedApr 15, 2020

IPO$8MUndisclosedOct 15, 2006

Seed$1MUndisclosedJun 15, 1996

Opportunities

Significant opportunities exist in the large, underserved markets of pancreatic cancer and post-viral syndromes like Long COVID.

Positive data from ongoing trials could lead to strategic partnerships, non-dilutive funding, or accelerated regulatory pathways.

Risk Factors

Key risks include clinical trial failures, dependence on a single lead asset (Ampligen), limited financial resources as a micro-cap company, intense competition in all target indications, and regulatory hurdles for approval.

Competitive Landscape

AIM faces competition from large pharmaceutical companies in oncology and smaller biotechs in the ME/CFS/Long COVID space. Its differentiation lies in Ampligen's unique TLR3 agonist mechanism and its extensive, long-term safety database from decades of clinical investigation.